Healthcare

• Clinical data from the Phase II Co-PSMA and Phase I/II COBRA trials supported the designation, demonstrating meaningfully improved diagnostic performance over the standard-of-care PSMA PET agents.

• Patrick Davies held 264,634 ordinary shares in Neuren Pharmaceuticals, held through Bond Street Custodians Limited asCustodianfor Austral 5065 Pty Ltd, of which Davies was a director.

On 21 September 2026, Telix Pharmaceuticals Limited (ASX:TLX) announced an agreement for a proposed combination with ITM. The upfront enterprise consideration is USD 1.65 billion on a cash-free, debt-free basis. The announced terms contemplate approximately USD 1.25 billion in Telix shares for ITM shareholders, …

The company's FY26 financial results, released on 18 August 2026, included approximately USD 7.1 billion in pre-taxImpairmentand related charges and USD 799 million in restructuring expenses.

Azenta reported USD 167 mn in fiscal fourth-quarter 2026 revenue from continuing operations, compared with USD 159 mn in the prior-year quarter. Reported growth was 5%, while organic growth was 2%. The company recorded adjustedDiluted Earnings per Sharefrom continuing operations of USD 0.28, compared …

Capricor submitted an amendment to its DeramiocelBiologicsLicense Application in August, adding two-year HOPE-3 open-label extension results and further analyses. The proposed refined indication focuses on upper-limbImpairmentin patients older than nine years. The FDA designated the addition a major amendment and extended its target action …

Carlsmed reported third-quarter 2026 revenue of USD 21.6 mn, an increase of 65% from the corresponding prior-year quarter. The company consequently raised its full-year revenue guidance to USD 78 mn–80 mn. The latest outlook follows earlier guidance of USD 74 mn–78 mn announced in …